Deep Genomics, now flush with cash, plans to take dozens of RNA therapies to the clinic

It was 2002 when Brendan Frey noticed a huge gap in biotech. The human genome had just been sequenced, allowing scientists to map genetic mutations. But there weren’t enough data to understand the consequences of those mutations, or really do much about them.

Predicting there would be an explosion of new data, Frey spent the next 13 years working on a way to sift through it all. Now, thanks to advances in RNA therapeutics, medicine is becoming programmable, Frey said. And on Wednesday, a slate of investors bet $180 million that his company’s AI platform can make sense of it.